PTC Therapeutics Inc
F:BH3
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
PTC Therapeutics Inc
F:BH3
|
US |
|
T
|
Trane Technologies PLC
XMUN:2IS
|
IE |
|
M
|
MERLIN Properties SOCIMI SA
ELI:MRL
|
ES |
|
B
|
Barrick Gold Corp
DUS:ABR
|
CA |
|
United Utilities Group PLC
OTC:UUGRY
|
UK |
|
C
|
CF Industries Holdings Inc
DUS:C4F
|
US |
Wall St Price Targets
BH3 Price Targets Summary
PTC Therapeutics Inc
According to Wall Street analysts, the average 1-year price target for BH3 is 73.6 EUR with a low forecast of 50.81 EUR and a high forecast of 107.37 EUR.
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
What is BH3's stock price target?
Price Target
73.6
EUR
According to Wall Street analysts, the average 1-year price target for BH3 is 73.6 EUR with a low forecast of 50.81 EUR and a high forecast of 107.37 EUR.
What is the Revenue forecast for PTC Therapeutics Inc?
Projected CAGR
2%
Over the last 13 years, the compound annual growth rate for Revenue has been 35%. The projected CAGR for the next 8 years is 2%.
What is the Operating Income forecast for PTC Therapeutics Inc?
Projected CAGR
-4%
The compound annual growth rate for Operating Income over the next 8 years is -4%.
What is the Net Income forecast for PTC Therapeutics Inc?
Projected CAGR
-3%
Over the last 13 years, the compound annual growth rate for Net Income has been 70%. The projected CAGR for the next 8 years is -3%.
